TMONYSEMeasuring & Controlling Devices, NECFiscal year ends December 31
THERMO FISHER SCIENTIFIC INC.
Financials through Q2 FY2026, quarter ended Jun 27, 2026Last filing: 10-Q on Jul 31, 2026
$679.38−10.62 (-1.54%)
Close on Oct 19, 2026
- Market cap
- $252.05B
- P/E (TTM)
- 36.6
- Dividend yield
- 0.25%
THERMO FISHER SCIENTIFIC INC. revenue by segment
By business segment
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Laboratory Products and Biopharma Services | $25.08B | $24.38B | $23.98B | $23.54B | $23.31B | – | $23.16B | – | – | – | – | – | 54.1% | +7.6% |
| Life Sciences Solutions | $10.99B | $10.67B | $10.37B | $10.03B | $9.83B | $9.69B | $9.63B | $9.50B | $9.54B | $9.65B | $9.98B | $10.56B | 23.7% | +11.7% |
| Analytical Instruments | $7.67B | $7.55B | $7.55B | $7.53B | $7.44B | $7.49B | $7.46B | $7.31B | $7.26B | $7.23B | $7.26B | $7.10B | 16.6% | +3.1% |
| Specialty Diagnostics | $4.74B | $4.67B | $4.68B | $4.61B | $4.57B | $4.55B | $4.51B | $4.46B | $4.41B | $4.41B | $4.41B | $4.42B | 10.2% | +3.8% |
| Laboratory Products and Biopharma Services | – | – | – | – | – | $22.88B | $23.00B | $22.75B | $22.74B | $22.81B | $22.89B | $23.06B | – | – |
| Operating income | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Life Sciences Solutions | $4.01B | $3.89B | $3.77B | $3.67B | $3.55B | $3.50B | $3.50B | $3.45B | $3.47B | $3.42B | $3.42B | $3.57B | +12.9% |
| Laboratory Products and Biopharma Services | $3.51B | $3.40B | $3.35B | $3.25B | $3.16B | – | $3.09B | – | – | – | – | – | +11.1% |
| Analytical Instruments | $1.79B | $1.69B | $1.74B | $1.82B | $1.84B | $1.96B | $1.96B | $1.88B | $1.89B | $1.89B | $1.91B | $1.80B | -2.7% |
| Specialty Diagnostics | $1.29B | $1.26B | $1.26B | $1.20B | $1.18B | $1.17B | $1.16B | $1.15B | $1.14B | $1.14B | $1.12B | $1.07B | +9.9% |
| Laboratory Products and Biopharma Services | – | – | – | – | – | $3.08B | $3.09B | $3.07B | $3.23B | $3.31B | $3.36B | $3.39B | – |
By product or service
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Product revenues | $26.84B | $26.26B | $25.97B | $25.49B | $25.15B | $25.06B | $25.03B | $24.68B | $24.69B | $24.79B | $25.24B | $25.78B | 57.9% | +6.7% |
| Service revenues | $19.50B | $18.94B | $18.59B | $18.25B | $18.07B | $17.84B | $17.85B | $17.69B | $17.66B | $17.70B | $17.61B | $17.64B | 42.1% | +7.9% |
| Consumables | – | $19.03B | $18.66B | $18.16B | $17.86B | $17.61B | $17.59B | $17.44B | $17.35B | $17.42B | $17.60B | $18.10B | – | – |
| Instruments | – | $7.23B | $7.30B | $7.33B | $7.29B | $7.45B | $7.45B | $7.24B | $7.34B | $7.38B | $7.65B | $7.68B | – | – |
By region
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| North America | $23.65B | $23.23B | $23.03B | $22.79B | $22.69B | $22.50B | $22.50B | $22.24B | $22.32B | $22.51B | $22.76B | $23.44B | 51.0% | +4.2% |
| Europe | $12.64B | $12.16B | $11.83B | $11.35B | $11.03B | $10.86B | $10.86B | $10.81B | $10.77B | $10.76B | $10.74B | $10.65B | 27.3% | +14.6% |
| Asia-Pacific | $8.36B | $8.18B | $8.10B | $8.03B | $7.94B | $7.99B | $7.96B | $7.83B | $7.82B | $7.75B | $7.87B | $7.84B | 18.1% | +5.4% |
| Other regions | $1.68B | $1.63B | $1.60B | $1.57B | $1.56B | $1.55B | $1.56B | $1.49B | $1.44B | $1.48B | $1.48B | $1.49B | 3.6% | +7.9% |
| United States | – | – | – | – | – | – | $21.76B | $21.48B | $21.56B | $21.75B | $22.01B | $22.70B | – | – |
| Other | – | – | – | – | – | – | $21.12B | $20.89B | $20.78B | $20.74B | $20.84B | $20.72B | – | – |
From the segment and revenue-disaggregation notes of Thermo Fisher Scientific's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.